This article was originally published in The Rose Sheet
Executive SummaryFragrance division revenues advanced 3.3% in local currencies, or 2.8% in Swiss francs, to $664.3 mil. (CHF1=$.78) for the nine month period, flavors and fragrances company announces. Despite a number of new launches, particularly in North America, fine fragrances business continued to perform below last year's level, firm notes. Consumer products sales within the fragrance division outperformed the market, with double-digit growth in North America, although fragrance ingredient sales were below the prior year level. Givaudan net sales during the period were up 1.6% in local currencies, or 1% in Swiss francs, to $1.63 bil., firm adds...
You may also be interested in...
Updated data from a postmarket study of Abiomed’s Impella RP right-heart pump further supports the device’s safety for a specific patient population.
The new US-Mexico-Canada (USMCA) trade agreement includes language on enhancing regulatory compatibility between the three countries by recognizing quality systems audits performed under the Medical Device Single Audit Program (MDSAP). It also stipulates that each trading partner “consider its resources and technical capacity” in ensuring the safety, effectiveness and quality of devices – and more. Medtech industry advocacy group AdvaMed is praising the deal, reached by the three countries on 10 December.
Novo Nordisk’s CEO talks to Scrip about the promise of glucose-responsive insulin, stem cell therapy, and a diabetes landscape without Sanofi.